INHALED INSULIN (AFREZZA®)


















  • Study drug was added to basal insulin. Baseline average A1C was around 8%.
Mealtime Afrezza vs mealtime Novolog in inadequately controlled T1DM for 24 weeks
Outcome Afrezza
(N=174)
Novolog
(N=170)
Change from baseline in HgA1C -0.21% -0.40%
Average daily dose of basal insulin 37 units 31.6 units
Average daily dose of study drug 115 units 26 units
Dropout rate 25% 11%





  • Study drug was added to oral meds. Baseline average A1C was around 8.3%.
Mealtime Afrezza vs Placebo in inadequately controlled T2DM for 24 weeks
Outcome Afrezza
(N=177)
Placebo inhaler
(N=176)
Change from baseline in HgA1C -0.82% -0.42%
Average daily dose of study drug 92 units N/A
Dropout rate 15% 21%








  • Data from trials involving Type 2 diabetics
Common side effects with Afrezza
Side effect Afrezza® Injectable insulin or oral meds
Cough 25.6% 5.4%
Throat pain or irritation 4.4% 0.9%
Headache 3.1% 1.8%
Diarrhea 2.7% 2.2%
Productive cough 2.2% 0.9%
Fatigue 2.0% 0.6%
Nausea 2.0% 1.0%


























Mealtime injected insulin dose Afrezza® dose
≤ 4 units 4 units
5 - 8 units 8 units
9 - 12 units 12 units
13 - 16 units 16 units
17 - 20 units 20 units
21 - 24 units 24 units